Cargando…
Managing Hypertension in the elderly: What’s new?
Hypertension is the leading modifiable risk factor for cardiovascular events and mortality in the world. Hypertension is a major risk factor for cardiovascular events and mortality in the elderly. The 2017 American College of Cardiology/American Heart Association hypertension guidelines recommend tr...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315374/ https://www.ncbi.nlm.nih.gov/pubmed/34327445 http://dx.doi.org/10.1016/j.ajpc.2020.100001 |
_version_ | 1783729708649676800 |
---|---|
author | Aronow, Wilbert S. |
author_facet | Aronow, Wilbert S. |
author_sort | Aronow, Wilbert S. |
collection | PubMed |
description | Hypertension is the leading modifiable risk factor for cardiovascular events and mortality in the world. Hypertension is a major risk factor for cardiovascular events and mortality in the elderly. The 2017 American College of Cardiology/American Heart Association hypertension guidelines recommend treatment of noninstitutionalized ambulatory community-dwelling persons aged 65 years and older with an average systolic blood pressure of 130 mm Hg or higher or a diastolic blood pressure of 80 mm Hg or higher with lifestyle measures plus antihypertensive drug to lower the blood pressure to less than 130/80 mm Hg For elderly adults with hypertension and a high burden of comorbidities and limited life expectancy, clinical judgment, patient preference, and a team-based approach to assess risk/benefit is reasonable for decisions about the intensity of SBP lowering and the choice of antihypertensive drugs to use for treatment. Randomized clinical trials need to be performed in frail elderly patients with hypertension living in nursing homes. Elderly frail persons with prevalent and frequent falls, marked cognitive impairment, and multiple comorbidities requiring multiple antihypertensive drugs also need to be included in randomized clinical trials. Data on patients older than 85 years treated for hypertension are also sparse. These patients need clinical trial data. Finally, the effect of different antihypertensive drugs on clinical outcomes including serious adverse events needs to be investigated in elderly frail patients with hypertension and different comorbidities. |
format | Online Article Text |
id | pubmed-8315374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-83153742021-07-28 Managing Hypertension in the elderly: What’s new? Aronow, Wilbert S. Am J Prev Cardiol State-of-the-Art Review Hypertension is the leading modifiable risk factor for cardiovascular events and mortality in the world. Hypertension is a major risk factor for cardiovascular events and mortality in the elderly. The 2017 American College of Cardiology/American Heart Association hypertension guidelines recommend treatment of noninstitutionalized ambulatory community-dwelling persons aged 65 years and older with an average systolic blood pressure of 130 mm Hg or higher or a diastolic blood pressure of 80 mm Hg or higher with lifestyle measures plus antihypertensive drug to lower the blood pressure to less than 130/80 mm Hg For elderly adults with hypertension and a high burden of comorbidities and limited life expectancy, clinical judgment, patient preference, and a team-based approach to assess risk/benefit is reasonable for decisions about the intensity of SBP lowering and the choice of antihypertensive drugs to use for treatment. Randomized clinical trials need to be performed in frail elderly patients with hypertension living in nursing homes. Elderly frail persons with prevalent and frequent falls, marked cognitive impairment, and multiple comorbidities requiring multiple antihypertensive drugs also need to be included in randomized clinical trials. Data on patients older than 85 years treated for hypertension are also sparse. These patients need clinical trial data. Finally, the effect of different antihypertensive drugs on clinical outcomes including serious adverse events needs to be investigated in elderly frail patients with hypertension and different comorbidities. Elsevier 2020-05-01 /pmc/articles/PMC8315374/ /pubmed/34327445 http://dx.doi.org/10.1016/j.ajpc.2020.100001 Text en © 2020 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | State-of-the-Art Review Aronow, Wilbert S. Managing Hypertension in the elderly: What’s new? |
title | Managing Hypertension in the elderly: What’s new? |
title_full | Managing Hypertension in the elderly: What’s new? |
title_fullStr | Managing Hypertension in the elderly: What’s new? |
title_full_unstemmed | Managing Hypertension in the elderly: What’s new? |
title_short | Managing Hypertension in the elderly: What’s new? |
title_sort | managing hypertension in the elderly: what’s new? |
topic | State-of-the-Art Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315374/ https://www.ncbi.nlm.nih.gov/pubmed/34327445 http://dx.doi.org/10.1016/j.ajpc.2020.100001 |
work_keys_str_mv | AT aronowwilberts managinghypertensionintheelderlywhatsnew |